Rally in DAX stocks intensifies, with a notable +13% increase possibly signaling the start of an ongoing surge.
Sartorius, a DAX-listed bioprocess solutions and lab products company, reported its Q3 results on Thursday, providing a mixed picture for investors.
Before the report, the stock had suffered a significant YTD loss of over 30 percent. However, there have been some recent positive movements, with the stock rising by 0.4 percent on August 13, 2025, and trading around €162.80 as of August 20, 2025.
In Q3, Sartorius' gross margin improved by 0.4 percentage points to 27.1 percent, but the adjusted EBITDA fell by 0.7 percent to 215.1 million euros due to the revenue decline. The order intake increased by 2.2 percent to 767.7 million euros, with the Lab Products & Services segment showing strong growth with a 3.9 percent increase in the order intake.
The stock rose by 6.2 percent in pre-market trading and continued to rise in the double-digits after trading started. However, the overall stock performance and analyst outlook remain mixed.
Some analysts express confidence in the numbers, such as James Vane-Tempest of Jefferies, who said the numbers should give the market confidence. On the other hand, RBC analyst Charles Weston criticized the revenue development but was positive about the confirmed annual forecast.
Despite the strong growth in the Lab Products & Services segment, the stock's overall YTD decline and high P/E ratio of around 69.7x for 2025 suggest that the stock may be expensive relative to earnings expectations. A recent forecast from mid-2025 suggested the stock might decline short-term by about 8%, indicating some negative momentum and caution among market watchers.
Analysts’ price targets remain in a relatively wide range—from about €210 to €235—indicating uncertainty about near-term upside. The stock needs to hold above 210 euros for the sideways phase to end and for positive momentum to drive further gains.
The company expects a low single-digit negative to low single-digit positive revenue development and an adjusted EBITDA margin of 27 to 29 percent for the year. The stock's performance in the coming days will be crucial in determining whether it has indeed entered a recovery phase.
Investors considering Sartorius should weigh the company’s long-term fundamentals and sector potential against current valuation and short-term risks. While the Q3 results showed some positive signs, the overall stock performance and analyst outlook remain cautious, suggesting that Sartorius has not yet clearly emerged from its downtrend on the DAX, and the stock may still face volatility.
[1] Source [2] Source [3] Source [4] Source
Investors looking at Sartorius should consider its current valuation and short-term risks, as the stock's high P/E ratio and recent forecasts suggest a potential short-term decline. However, the company's strong growth in the Lab Products & Services segment presents an opportunity for investing in the stock market. Despite showing some positive signs in the Q3 results, analysts’ price targets indicate uncertainty about near-term upside, suggesting that Sartorius may continue to face volatility in the stock-market.
